Lexicon Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$26.0M
Doctors Paid
16,030
Transactions
43,970
2024 Total
$10.7M
Payment Breakdown by Category
Research$21.2M (81.6%)
Consulting$1.2M (4.6%)
Food & Beverage$1.0M (3.9%)
Travel$404,999 (1.6%)
Royalty/License$10,000 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.2M | 2,141 | 81.6% |
| Honoraria | $1.5M | 528 | 5.8% |
| Consulting Fee | $1.2M | 250 | 4.6% |
| Food and Beverage | $1.0M | 39,209 | 3.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $528,444 | 231 | 2.0% |
| Travel and Lodging | $404,999 | 1,520 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $76,895 | 31 | 0.3% |
| Grant | $66,200 | 5 | 0.3% |
| Royalty or License | $10,000 | 1 | 0.0% |
| Education | $622.22 | 54 | 0.0% |
Payments by Type
Research
$21.2M
2,141 transactions
General
$4.8M
41,829 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| LX9211 | $4.0M | 49 | 634 |
| LX9211.1-104-QTC | $3.2M | 0 | 28 |
| LX9211.1-204-DPN | $3.1M | 0 | 464 |
| EFC-14875 | $1.7M | 0 | 103 |
| LX2761.102 | $1.6M | 0 | 41 |
| LX4211.309 | $1.4M | 0 | 232 |
| LX4211.1-312-T1DM | $902,162 | 0 | 166 |
| LX1606.1-110-NRM | $751,083 | 0 | 7 |
| LX4211.1-121-REN | $483,905 | 0 | 41 |
| LX9211.1-201-DPN | $456,000 | 0 | 10 |
| LX1606.1-207-BTC | $449,529 | 0 | 26 |
| RELIEF-PHN1 | $383,726 | 0 | 82 |
| EFC-15294 | $292,887 | 0 | 11 |
| LX1606.1-111-HEP | $267,349 | 0 | 30 |
| EFC15156 | $126,772 | 0 | 16 |
| TPH1 | $121,593 | 0 | 1 |
| EFC15294 | $116,424 | 0 | 17 |
| SONATA-HCM | $111,874 | 13 | 51 |
| EFC14868 | $97,180 | 0 | 17 |
| RELIEF-DPN 1 | $93,716 | 0 | 27 |
| Effects of Sotagliflozin in regulation of clotting | $90,993 | 0 | 1 |
| Effects of SGLT2 vs SGLT1/2 | $71,715 | 0 | 6 |
| The Potential Population Health Impact of treating Type 2 Diabetes with Sotagliflozin | $68,301 | 0 | 1 |
| EFC-15166 | $64,930 | 0 | 13 |
| LX4211.1.204 | $58,418 | 0 | 6 |
| Diabetes with Scotaglifiozin | $56,520 | 0 | 1 |
| IIS Telotristat Ethyl | $53,504 | 0 | 2 |
| IIS | $52,909 | 0 | 2 |
| Preclinical Studies of Sotagliflozin in Hypertrophic Cardiomyopathy | $51,854 | 0 | 1 |
| EFC-14837 | $50,280 | 0 | 19 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Robert Lefkowitz, M.d, M.D | Cardiovascular Disease | Durham, NC | $263,180 | $0 |
| Michael Morse, M.d, M.D | Hematology & Oncology | Durham, NC | $163,539 | $0 |
| Dr. Daneng Li, M.d, M.D | Internal Medicine | Duarte, CA | $128,107 | $0 |
| Eric Liu, M.d, M.D | Surgical Oncology | Denver, CO | $92,196 | $0 |
| Dr. Judith Swain, Md, MD | Cardiovascular Disease | La Jolla, CA | $88,035 | $0 |
| Dr. Jerome Zacks, M.d, M.D | Cardiovascular Disease | New York, NY | $76,414 | $0 |
| Dr. Krishnaswami Vijayaraghavan, M.d, M.D | Cardiovascular Disease | Scottsdale, AZ | $75,428 | $0 |
| Dr. Stephen Greene, M.d, M.D | Internal Medicine | Durham, NC | $61,596 | $0 |
| Dr. Hal Gerstein, Md, MD | Hematology & Oncology | Great Neck, NY | $61,453 | $0 |
| Dr. Joggy George, M.d, M.D | Internal Medicine | Houston, TX | $58,761 | $0 |
| Henry Ward, M.d, M.D | Cardiovascular Disease | New Haven, CT | $57,371 | $0 |
| Raghavendra Charan Makam, Md, MD | Internal Medicine | Vero Beach, FL | $56,690 | $0 |
| Americo Simonini, Md, MD | Cardiovascular Disease | Los Angeles, CA | $54,376 | $0 |
| Dr. Rodney Samaan, Md, MD | Cardiovascular Disease | Mission Hills, CA | $54,288 | $0 |
| Matthew Budoff, M.d, M.D | Cardiovascular Disease | Torrance, CA | $52,634 | $0 |
| Dr. Norman Lepor, M.d, M.D | Specialist | Beverly Hills, CA | $51,909 | $0 |
| Dr. Harvey Serota, M.d, M.D | Cardiovascular Disease | Saint Louis, MO | $48,745 | $0 |
| Dr. Kenneth Burnham, Md, MD | Cardiovascular Disease | Mobile, AL | $48,722 | $0 |
| Hunter Champion, M.d, M.D | Cardiovascular Disease | Columbus, GA | $47,714 | $0 |
| Dr. Sukhdeep Basra, M.d, M.D | Internal Medicine | Houston, TX | $46,851 | $0 |
| Salim Hayek, M.d, M.D | Internal Medicine | Ann Arbor, MI | $45,212 | $0 |
| Dr. John Ryan, Mbbchbao, MBBCHBAO | Cardiovascular Disease | Salt Lake City, UT | $44,828 | $0 |
| Dr. Russell Canham, M.d, M.D | Clinical Cardiac Electrophysiology | Dallas, TX | $43,232 | $0 |
| Dr. Tannaz Armaghany, M.d, M.D | Hematology & Oncology | Houston, TX | $42,826 | $0 |
| Muthiah Vaduganathan, Md, Mph, MD, MPH | Cardiovascular Disease | Boston, MA | $42,731 | $0 |
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. has made $26.0M in payments to 16,030 healthcare providers, recorded across 43,970 transactions in the CMS Open Payments database. In 2024, the company paid $10.7M. The top product by payment volume is Inpefa ($2.3M).
Payments were distributed across 152 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($1.7M to 3,554 doctors).
Payment categories include: Food & Beverage ($1.0M), Consulting ($1.2M), Research ($21.2M), Travel & Lodging ($404,999), Royalties ($10,000).
Lexicon Pharmaceuticals, Inc. is associated with 1 products in the CMS Open Payments database.